肌酸激酶脑型亚基对前列腺癌细胞体内外生长的影响。

Effect of CKBM on prostate cancer cell growth in vitro and in vivo.

作者信息

Liu Edgar S L, Luk Sharon C W, Leung Eric T Y, Lee Wai-Him, Yuen Wai-Fan, Kwok Kei-Ming, Siu Stephanie W F, Kwok Nga-Sze, Xing Hong-Tao, Wu Madeline, Pang Shiu-Fun

机构信息

CK Life Sciences International Inc., Tai Po Industrial Estate, Hong Kong.

出版信息

J Chemother. 2008 Apr;20(2):246-52. doi: 10.1179/joc.2008.20.2.246.

DOI:10.1179/joc.2008.20.2.246

PMID:18467253

Abstract

Prostate carcinoma and metastasis are common among male subjects worldwide. CKBM is a drug product targeting prostate cancer in multiple ways. Prostate cancer cell lines PC3 and DU145 were treated with CKBM. The effect of CKBM on the cell's viability, cell cycle, adhesive and invasive properties and its growth in an animal model were assessed. Results indicated that CKBM inhibited PC3 and DU145 cell growth in vitro at IC(50 )values 3.923 and 4.697% respectively, and it brought about cell cycle arrest at G2/M phase. CKBM also attenuated DU145 cells to invade and adhere to extracellular matrices including Matrigel, laminin, fibronectin and collagen IV. Moreover, PC3 tumor xenograft growth was inhibited by over 60% after 28-day of 0.2, 0.4 or 0.8 ml/day CKBM treatment. The present study indicates that CKBM is effective against prostate cancer cell growth in vitro and in vivo. Further studies are required to elucidate its mechanism of action.

摘要

前列腺癌及其转移在全球男性中很常见。CKBM是一种以多种方式靶向前列腺癌的药物产品。用CKBM处理前列腺癌细胞系PC3和DU145。评估了CKBM对细胞活力、细胞周期、黏附及侵袭特性以及其在动物模型中生长的影响。结果表明，CKBM在体外分别以3.923%和4.697%的IC(50)值抑制PC3和DU145细胞生长，并使细胞周期停滞于G2/M期。CKBM还减弱了DU145细胞对包括基质胶、层粘连蛋白、纤连蛋白和IV型胶原在内的细胞外基质的侵袭和黏附。此外，在每天给予0.2、0.4或0.8 ml CKBM处理28天后，PC3肿瘤异种移植的生长被抑制了60%以上。本研究表明，CKBM在体外和体内均对前列腺癌细胞生长有效。需要进一步研究以阐明其作用机制。